Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
47 hedge funds and large institutions have $216M invested in Intra-Cellular Therapies Inc. in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 5 closing their positions.
30% more capital invested
Capital invested by funds: $166M → $216M (+$49.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
4% less funds holding
Funds holding: 49 → 47 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.15M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$781K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$689K |
| 4 |
Morgan Stanley
New York
|
+$466K |
| 5 |
State Street
Boston,
Massachusetts
|
+$247K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$952K |
| 2 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$515K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$198K |
| 4 |
Goldman Sachs
New York
|
-$149K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$140K |
ITCI Hedge Fund Activity: Q4 2014 in Review
47 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2014, worth a combined $216M — up 30% from $166M a quarter earlier.
Fund positioning in ITCI was balanced in Q4 2014: 5 funds opened new positions, 5 closed out, 16 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $1.15M. The largest seller was Franklin Resources, cutting an estimated $952K.
- 47 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2014, down from 49 in Q3 2014.
- Funds reported $216M of Intra-Cellular Therapies Inc. stock for Q4 2014, up 30% quarter-over-quarter.
- 5 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2014 and 5 closed out, a net change of 0 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2014 was BlackRock Fund Advisors, an estimated $1.15M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2014 was Franklin Resources, an estimated $952K sold.
Based on aggregated 13F filings for Q4 2014.